Literature DB >> 10393893

The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses.

G R Uhl1, I Sora, Z Wang.   

Abstract

There are differences between human individuals and between mouse strains in levels of mu opiate receptor (muOR) expression, responses to painful stimuli, and responses to opiate drugs. One of the best candidates for contributing to these differences is variation at the muOR gene locus. Support for this idea comes from analyses of the human and murine muOR genes. Assessments of individual differences in human muOR expression add further support. Studies with mice, including knockout-transgenic, quantitative trait locus, and strain-comparison studies, also strongly support the possibility that muOR gene alleles would be strong candidates for contributing to individual differences in human nociception and opiate drug responses. This paper reviews current analyses of the murine and human muOR genes, their important variants, and correlations between these variants and opiate influences on pain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10393893      PMCID: PMC33614          DOI: 10.1073/pnas.96.14.7752

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Opiate receptors in mice: genetic differences.

Authors:  A Baran; L Shuster; B E Eleftheriou; D W Bailey
Journal:  Life Sci       Date:  1975-08-15       Impact factor: 5.037

2.  The human mu opioid receptor gene: 5' regulatory and intronic sequences.

Authors:  B Wendel; M R Hoehe
Journal:  J Mol Med (Berl)       Date:  1998-06       Impact factor: 4.599

3.  Familial typical migraine: linkage to chromosome 19p13 and evidence for genetic heterogeneity.

Authors:  D R Nyholt; R A Lea; P J Goadsby; P J Brimage; L R Griffiths
Journal:  Neurology       Date:  1998-05       Impact factor: 9.910

4.  Opiate receptor binding sites in human brain.

Authors:  A Pfeiffer; A Pasi; P Mehraein; A Herz
Journal:  Brain Res       Date:  1982-09-23       Impact factor: 3.252

5.  Visceral chemical nociception in mice lacking mu-opioid receptors: effects of morphine, SNC80 and U-50,488.

Authors:  I Sora; X F Li; M Funada; S Kinsey; G R Uhl
Journal:  Eur J Pharmacol       Date:  1999-02-05       Impact factor: 4.432

6.  Multicompartmental analysis of [11C]-carfentanil binding to opiate receptors in humans measured by positron emission tomography.

Authors:  J J Frost; K H Douglass; H S Mayberg; R F Dannals; J M Links; A A Wilson; H T Ravert; W C Crozier; H N Wagner
Journal:  J Cereb Blood Flow Metab       Date:  1989-06       Impact factor: 6.200

7.  Analgesic, locomotor and lethal effects of morphine in the mouse: strain comparisons.

Authors:  A S Moskowitz; G W Terman; K R Carter; M J Morgan; J C Liebeskind
Journal:  Brain Res       Date:  1985-12-30       Impact factor: 3.252

8.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

9.  Examination of the involvement of supraspinal and spinal mu and delta opioid receptors in analgesia using the mu receptor deficient CXBK mouse.

Authors:  J L Vaught; J R Mathiasen; R B Raffa
Journal:  J Pharmacol Exp Ther       Date:  1988-04       Impact factor: 4.030

10.  Comparison of the effects of morphine on locomotor activity, analgesia and primary and protracted physical dependence in six mouse strains.

Authors:  D A Brase; H H Loh; E L Way
Journal:  J Pharmacol Exp Ther       Date:  1977-05       Impact factor: 4.030

View more
  51 in total

Review 1.  The neurobiology of pain.

Authors:  R Dubner; M Gold
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

2.  Structural basis for μ-opioid receptor binding and activation.

Authors:  Adrian W R Serohijos; Shuangye Yin; Feng Ding; Josee Gauthier; Dustin G Gibson; William Maixner; Nikolay V Dokholyan; Luda Diatchenko
Journal:  Structure       Date:  2011-11-09       Impact factor: 5.006

3.  [Are polymorphisms in the mu-opioid receptor important for opioid therapy?].

Authors:  J Lötsch; R Freynhagen; G Geisslinger
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

4.  Modification of morphine-induced hyperlocomotion and antinociception in mice by clorgyline, a monoamine oxidase-A inhibitor.

Authors:  Nobue Kitanaka; Junichi Kitanaka; Motohiko Takemura
Journal:  Neurochem Res       Date:  2006-06-23       Impact factor: 3.996

Review 5.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

6.  Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence.

Authors:  Huiping Zhang; Xingguang Luo; Henry R Kranzler; Jaakko Lappalainen; Bao-Zhu Yang; Evgeny Krupitsky; Edwin Zvartau; Joel Gelernter
Journal:  Hum Mol Genet       Date:  2006-02-13       Impact factor: 6.150

Review 7.  G-protein-coupled receptors in adult neurogenesis.

Authors:  Van A Doze; Dianne M Perez
Journal:  Pharmacol Rev       Date:  2012-05-18       Impact factor: 25.468

Review 8.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

9.  Bioinformatic analysis of the human mu opioid receptor (OPRM1) splice and polymorphic variants.

Authors:  Lili Xin; Zaijie Jim Wang
Journal:  AAPS PharmSci       Date:  2002

10.  OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.

Authors:  Gabor Oroszi; Raymond F Anton; Stephanie O'Malley; Robert Swift; Helen Pettinati; David Couper; Qiaoping Yuan; David Goldman
Journal:  Alcohol Clin Exp Res       Date:  2008-11-25       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.